6 O
ADVERSE O
REACTIONS O
The O
following O
important O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Lower B-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
Amputation I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hypotension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Ketoacidosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Acute B-OSE_Labeled_AE
Kidney I-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Impairment B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Renal I-OSE_Labeled_AE
Function I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Urosepsis B-OSE_Labeled_AE
and O
Pyelonephritis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hypoglycemia B-NonOSE_AE
with O
Concomitant O
Use O
with O
Insulin O
and O
Insulin O
Secretagogues O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Genital B-OSE_Labeled_AE
Mycotic I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Bone B-OSE_Labeled_AE
Fracture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Low I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Density I-OSE_Labeled_AE
Lipoprotein I-OSE_Labeled_AE
( O
LDL-C O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Most O
common O
adverse O
reactions O
associated O
with O
INVOKANA O
( O
5 O
% O
or O
greater O
incidence O
) O
: O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-526-7736 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
the O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Pool O
of O
Placebo-Controlled O
Trials O
The O
data O
in O
Table O
1 O
is O
derived O
from O
four O
26-week O
placebo-controlled O
trials O
. O

In O
one O
trial O
INVOKANA O
was O
used O
as O
monotherapy O
and O
in O
three O
trials O
INVOKANA O
was O
used O
as O
add-on O
therapy O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

These O
data O
reflect O
exposure O
of O
1667 O
patients O
to O
INVOKANA O
and O
a O
mean O
duration O
of O
exposure O
to O
INVOKANA O
of O
24 O
weeks O
. O

Patients O
received O
INVOKANA O
100 O
mg O
( O
N=833 O
) O
, O
INVOKANA O
300 O
mg O
( O
N=834 O
) O
or O
placebo O
( O
N=646 O
) O
once O
daily O
. O

The O
mean O
age O
of O
the O
population O
was O
56 O
years O
and O
2 O
% O
were O
older O
than O
75 O
years O
of O
age O
. O

Fifty O
percent O
( O
50 O
% O
) O
of O
the O
population O
was O
male O
and O
72 O
% O
were O
Caucasian O
, O
12 O
% O
were O
Asian O
, O
and O
5 O
% O
were O
Black O
or O
African O
American O
. O

At O
baseline O
the O
population O
had O
diabetes B-Not_AE_Candidate
for O
an O
average O
of O
7.3 O
years O
, O
had O
a O
mean O
HbA1Cof O
8.0 O
% O
and O
20 O
% O
had O
established O
microvascular B-Not_AE_Candidate
complications I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

Baseline O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
was O
normal O
or O
mildly I-Not_AE_Candidate
impaired I-Not_AE_Candidate
( O
mean O
eGFR B-Not_AE_Candidate
8 I-Not_AE_Candidate
8 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
. O

Table O
1 O
shows O
common O
adverse O
reactions O
associated O
with O
the O
use O
of O
INVOKANA O
. O

These O
adverse O
reactions O
were O
not O
present O
at O
baseline O
, O
occurred O
more O
commonly O
on O
INVOKANA O
than O
on O
placebo O
, O
and O
occurred O
in O
at O
least O
2 O
% O
of O
patients O
treated O
with O
either O
INVOKANA O
100 O
mg O
or O
INVOKANA O
300 O
mg O
. O
Table O
1 O
: O
Adverse O
Reactions O
From O
Pool O
of O
Four O
26-Week O
Placebo-Controlled O
Studies O
Reported O
in O
> O
= O
2 O
% O
of O
INVOKANA-Treated O
PatientsThe O
four O
placebo-controlled O
trials O
included O
one O
monotherapy O
trial O
and O
three O
add-on O
combination O
trials O
with O
metformin O
, O
metformin O
and O
sulfonylurea O
, O
or O
metformin O
and O
pioglitazone O
. O

Note O
: O
Percentages O
were O
weighted O
by O
studies O
. O

Study O
weights O
were O
proportional O
to O
the O
harmonic O
mean O
of O
the O
three O
treatment O
sample O
sizes O
. O

Adverse O
Reaction O
PlaceboN=646 O
INVOKANA O
100 O
mgN=833 O
INVOKANA O
300 O
mgN=834 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
note O
: O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
include O
the O
following O
adverse O
reactions O
: O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
Cystitis B-OSE_Labeled_AE
, O
Kidney B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
Urosepsis B-OSE_Labeled_AE
. O
] O

3.8 O
% O
5.9 O
% O
4.4 O
% O
Increased B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
[ O
note O
: O
Increased B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
includes O
the O
following O
adverse O
reactions O
: O
Polyuria B-OSE_Labeled_AE
, O
Pollakiuria B-OSE_Labeled_AE
, O
Urine B-OSE_Labeled_AE
output I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Micturition B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
and O
Nocturia B-OSE_Labeled_AE
. O
] O

0.7 O
% O
5.1 O
% O
4.6 O
% O
Thirst B-OSE_Labeled_AE
[ O
note O
: O
Thirst O
includes O
the O
following O
adverse O
reactions O
: O
Thirst B-OSE_Labeled_AE
, O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
and O
Polydipsia B-OSE_Labeled_AE
. O
] O

0.1 O
% O
2.8 O
% O
2.4 O
% O
Constipation B-OSE_Labeled_AE
0.9 O
% O
1.8 O
% O
2.4 O
% O
Nausea B-OSE_Labeled_AE
1.6 O
% O
2.1 O
% O
2.3 O
% O
N=312 O
N=425 O
N=430 O
Female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
note O
: O
Female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
include O
the O
following O
adverse O
reactions O
: O
Vulvovaginal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
Vulvovaginal B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
Vulvovaginitis B-OSE_Labeled_AE
, O
Vaginal B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
Vulvitis B-OSE_Labeled_AE
, O
and O
Genital B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
. O
] O

2.8 O
% O
10.6 O
% O
11.6 O
% O
Vulvovaginal B-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
0.0 O
% O
1.6 O
% O
3.2 O
% O
N=334 O
N=408 O
N=404 O
Male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
note O
: O
Male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
s O
include O
the O
following O
adverse O
reactions O
: O
Balanitis B-OSE_Labeled_AE
or O
Balanoposthitis B-OSE_Labeled_AE
, O
Balanitis B-OSE_Labeled_AE
candida I-OSE_Labeled_AE
, O
and O
Genital B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
. O
] O

0.7 O
% O
4.2 O
% O
3.8 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
was O
also O
more O
commonly O
reported O
in O
patients O
taking O
INVOKANA O
100 O
mg O
( O
1.8 O
% O
) O
, O
300 O
mg O
( O
1.7 O
% O
) O
than O
in O
patients O
taking O
placebo O
( O
0.8 O
% O
) O
. O

Pool O
of O
Placebo- O
and O
Active-Controlled O
Trials O
The O
occurrence O
of O
adverse O
reactions O
for O
canagliflozin O
was O
evaluated O
in O
a O
larger O
pool O
of O
patients O
participating O
in O
placebo- O
and O
active-controlled O
trials O
. O

The O
data O
combined O
eight O
clinical O
trials O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
and O
reflect O
exposure O
of O
6177 O
patients O
to O
INVOKANA O
. O

The O
mean O
duration O
of O
exposure O
to O
INVOKANA O
was O
38 O
weeks O
with O
1832 O
individuals O
exposed O
to O
INVOKANA O
for O
greater O
than O
50 O
weeks O
. O

Patients O
received O
INVOKANA O
100 O
mg O
( O
N=3092 O
) O
, O
INVOKANA O
300 O
mg O
( O
N=3085 O
) O
or O
comparator O
( O
N=3262 O
) O
once O
daily O
. O

The O
mean O
age O
of O
the O
population O
was O
60 O
years O
and O
5 O
% O
were O
older O
than O
75 O
years O
of O
age O
. O

Fifty-eight O
percent O
( O
58 O
% O
) O
of O
the O
population O
was O
male O
and O
73 O
% O
were O
Caucasian O
, O
16 O
% O
were O
Asian O
, O
and O
4 O
% O
were O
Black O
or O
African O
American O
. O

At O
baseline O
, O
the O
population O
had O
diabetes B-Not_AE_Candidate
for O
an O
average O
of O
11 O
years O
, O
had O
a O
mean O
HbA1Cof O
8.0 O
% O
and O
33 O
% O
had O
established O
microvascular B-Not_AE_Candidate
complications I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

Baseline O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
was I-Not_AE_Candidate
normal I-Not_AE_Candidate
or I-Not_AE_Candidate
mildly I-Not_AE_Candidate
impaired I-Not_AE_Candidate
( O
mean O
eGFR B-Not_AE_Candidate
8 I-Not_AE_Candidate
1 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
. O

The O
types O
and O
frequency O
of O
common O
adverse O
reactions O
observed O
in O
the O
pool O
of O
eight O
clinical O
trials O
were O
consistent O
with O
those O
listed O
in O
Table O
1 O
. O

Percentages O
were O
weighted O
by O
studies O
. O

Study O
weights O
were O
proportional O
to O
the O
harmonic O
mean O
of O
the O
three O
treatment O
sample O
sizes O
. O

In O
this O
pool O
, O
INVOKANA O
was O
also O
associated O
with O
the O
adverse O
reactions O
of O
fatigue B-OSE_Labeled_AE
( O
1.8 O
% O
with O
comparator O
, O
2.2 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
2.0 O
% O
with O
INVOKANA O
300 O
mg O
) O
and O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
strength I-OSE_Labeled_AE
or I-OSE_Labeled_AE
energy I-OSE_Labeled_AE
( O
i.e. O
, O
asthenia B-OSE_Labeled_AE
) O
( O
0.6 O
% O
with O
comparator O
, O
0.7 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
1.1 O
% O
with O
INVOKANA O
300 O
mg O
) O
. O

In O
the O
pool O
of O
eight O
clinical O
trials O
, O
the O
incidence O
rate O
of O
pancreatitis B-OSE_Labeled_AE
( O
acute O
or O
chronic I-OSE_Labeled_AE
) O
was O
0.1 O
% O
, O
0.2 O
% O
, O
and O
0.1 O
% O
receiving O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

In O
the O
pool O
of O
eight O
clinical O
trials O
, O
hypersensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
erythema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
angioedema B-OSE_Labeled_AE
) O
occurred O
in O
3.0 O
% O
, O
3.8 O
% O
, O
and O
4.2 O
% O
of O
patients O
receiving O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Five O
patients O
experienced O
serious O
adverse O
reactions O
of O
hypersensitivity B-OSE_Labeled_AE
with O
INVOKANA O
, O
which O
included O
4 O
patients O
with O
urticaria B-OSE_Labeled_AE
and O
1 O
patient O
with O
a O
diffuse B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
and O
urticaria B-OSE_Labeled_AE
occurring O
within O
hours O
of O
exposure O
to O
INVOKANA O
. O

Among O
these O
patients O
, O
2 O
patients O
discontinued O
INVOKANA O
. O

One O
patient O
with O
urticaria B-OSE_Labeled_AE
had O
recurrence O
when O
INVOKANA O
was O
re-initiated O
. O

Photosensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
polymorphic B-OSE_Labeled_AE
light I-OSE_Labeled_AE
eruption I-OSE_Labeled_AE
, O
and O
sunburn B-OSE_Labeled_AE
) O
occurred O
in O
0.1 O
% O
, O
0.2 O
% O
, O
and O
0.2 O
% O
of O
patients O
receiving O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Other O
adverse O
reactions O
occurring O
more O
frequently O
on O
INVOKANA O
than O
on O
comparator O
were O
: O
Lower O
Limb O
Amputation O
An O
approximately O
2-fold O
increased O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
associated O
with O
INVOKANA O
use O
was O
observed O
in O
CANVAS O
and O
CANVAS-R O
, O
two O
large O
, O
randomized O
, O
placebo-controlled O
trials O
evaluating O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
who O
had O
either O
established O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
were O
at O
risk O
for O
cardiovascular B-NonOSE_AE
disease I-NonOSE_AE
. O

Patients O
in O
CANVAS O
and O
CANVAS-R O
were O
followed O
for O
an O
average O
of O
5.7 O
and O
2.1 O
years O
, O
respectively O
. O

The O
amputation B-NonOSE_AE
data O
for O
CANVAS O
and O
CANVAS-R O
are O
shown O
in O
Tables O
2 O
and O
3 O
, O
respectively O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Table O
2 O
: O
CANVAS O
Amputations O
PlaceboN=1441 O
INVOKANA O
100 O
mgN=1445 O
INVOKANA O
300 O
mgN=1441 O
INVOKANA O
( O
Pooled O
) O
N=2886 O
Note O
: O
Incidence O
is O
based O
on O
the O
number O
of O
patients O
with O
at O
least O
one O
amputation B-NonOSE_AE
, O
and O
not O
the O
total O
number O
of O
amputation B-NonOSE_AE
events O
. O

A O
patient O
's O
follow-up O
is O
calculated O
from O
Day O
1 O
to O
the O
first O
amputation B-NonOSE_AE
event O
date O
. O

Some O
patients O
had O
more O
than O
one O
amputation B-NonOSE_AE
. O

Patients O
with O
an O
amputation B-OSE_Labeled_AE
, O
n O
( O
% O
) O
22 O
( O
1.5 O
) O
50 O
( O
3.5 O
) O
45 O
( O
3.1 O
) O
95 O
( O
3.3 O
) O
Total O
amputations B-OSE_Labeled_AE
33 O
83 O
79 O
162 O
Amputation B-OSE_Labeled_AE
incidence O
rate O
( O
per O
1000 O
patient-years O
) O
2.8 O
6.2 O
5.5 O
5.9 O
Hazard O
Ratio O
( O
95 O
% O
CI O
) O
-- O
2.24 O
( O
1.36 O
, O
3.69 O
) O
2.01 O
( O
1.20 O
, O
3.34 O
) O
2.12 O
( O
1.34 O
, O
3.38 O
) O
Table O
3 O
: O
CANVAS-R O
Amputations O
PlaceboN=2903 O
INVOKANA O
100 O
mg O
( O
with O
up-titration O
to O
300 O
mg O
) O
N=2904 O
Note O
: O
Incidence O
is O
based O
on O
the O
number O
of O
patients O
with O
at O
least O
one O
amputation B-NonOSE_AE
, O
and O
not O
the O
total O
number O
of O
amputation B-NonOSE_AE
events I-NonOSE_AE
. O

A O
patient O
's O
follow-up O
is O
calculated O
from O
Day O
1 O
to O
the O
first O
amputation B-NonOSE_AE
event O
date O
. O

Some O
patients O
had O
more O
than O
one O
amputation B-NonOSE_AE
. O

Patients O
with O
an O
amputation B-OSE_Labeled_AE
, O
n O
( O
% O
) O
25 O
( O
0.9 O
) O
45 O
( O
1.5 O
) O
Total O
amputations B-OSE_Labeled_AE
36 O
59 O
Amputation B-OSE_Labeled_AE
incidence O
rate O
( O
per O
1000 O
patient-years O
) O
4.2 O
7.5 O
Hazard O
Ratio O
( O
95 O
% O
CI O
) O
-- O
1.80 O
( O
1.10 O
, O
2.93 O
) O
Volume O
Depletion-Related O
Adverse O
Reactions O
INVOKANA O
results O
in O
an O
osmotic O
diuresis O
, O
which O
may O
lead O
to O
reductions B-OSE_Labeled_AE
in I-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
. O

In O
clinical O
studies O
, O
treatment O
with O
INVOKANA O
was O
associated O
with O
a O
dose-dependent O
increase O
in O
the O
incidence O
of O
volume B-OSE_Labeled_AE
depletion I-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
hypotension B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
dizziness I-OSE_Labeled_AE
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
and O
dehydration B-OSE_Labeled_AE
) O
. O

An O
increased O
incidence O
was O
observed O
in O
patients O
on O
the O
300 O
mg O
dose O
. O

The O
three O
factors O
associated O
with O
the O
largest O
increase O
in O
volume B-NonOSE_AE
depletion I-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
the O
use O
of O
loop O
diuretics O
, O
moderate B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
eGFR B-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
and O
age O
75 O
years O
and O
older O
( O
Table O
4 O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.5 O
and O
8.6 O
) O
] O
. O

Table O
4 O
: O
Proportion O
of O
Patients O
With O
at O
Least O
One O
Volume B-OSE_Labeled_AE
Depletion I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
( O
Pooled O
Results O
from O
8 O
Clinical O
Trials O
) O
Baseline O
Characteristic O
Comparator O
Group O
[ O
note O
: O
Includes O
placebo O
and O
active-comparator O
groups O
] O
% O
INVOKANA O
100 O
mg O
% O
INVOKANA O
300 O
mg O
% O
Overall O
population O
1.5 O
% O
2.3 O
% O
3.4 O
% O
75 O
years O
of O
age O
and O
older O
[ O
note O
: O
Patients O
could O
have O
more O
than O
1 O
of O
the O
listed O
risk O
factors O
] O
2.6 O
% O
4.9 O
% O
8.7 O
% O
eGFR B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
2.5 O
% O
4.7 O
% O
8.1 O
% O
Use O
of O
loop O
diuretic O
4.7 O
% O
3.2 O
% O
8.8 O
% O
Falls O
In O
a O
pool O
of O
nine O
clinical O
trials O
with O
mean O
duration O
of O
exposure O
to O
INVOKANA O
of O
85 O
weeks O
, O
the O
proportion O
of O
patients O
who O
experienced O
falls B-OSE_Labeled_AE
was O
1.3 O
% O
, O
1.5 O
% O
, O
and O
2.1 O
% O
with O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

The O
higher O
risk O
of O
falls B-OSE_Labeled_AE
for O
patients O
treated O
with O
INVOKANA O
was O
observed O
within O
the O
first O
few O
weeks O
of O
treatment O
. O

Impairment O
in O
Renal O
Function O
INVOKANA O
is O
associated O
with O
a O
dose-dependent O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
and O
a O
concomitant O
fall B-OSE_Labeled_AE
in I-OSE_Labeled_AE
estimated I-OSE_Labeled_AE
GFR I-OSE_Labeled_AE
( O
Table O
5 O
) O
. O

Patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
at O
baseline O
had O
larger O
mean O
changes O
. O

Table O
5 O
: O
Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Serum O
Creatinine O
and O
eGFR I-OSE_Labeled_AE
Associated O
with O
INVOKANA O
in O
the O
Pool O
of O
Four O
Placebo-Controlled O
Trials O
and O
Moderate O
Renal O
Impairment O
Trial O
PlaceboN=646 O
INVOKANA O
100 O
mgN=833 O
INVOKANA O
300 O
mgN=834 O
Pool O
of O
Four O
Placebo-Controlled O
Trials O
Baseline O
Creatinine O
( O
mg/dL O
) O
0.84 O
0.82 O
0.82 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
87.0 O
88.3 O
88.8 O
Week O
6 O
Change O
Creatinine O
( O
mg/dL O
) O
0.01 O
0.03 O
0.05 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-1.6 O
-3.8 O
-5.0 O
End O
of O
Treatment O
Change O
[ O
note O
: O
Week O
26 O
in O
mITT O
LOCF O
population O
] O
Creatinine O
( O
mg/dL O
) O
0.01 O
0.02 O
0.03 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-1.6 O
-2.3 O
-3.4 O
PlaceboN=90 O
INVOKANA O
100 O
mgN=90 O
INVOKANA O
300 O
mgN=89 O
Moderate B-Not_AE_Candidate
Renal I-Not_AE_Candidate
Impairment I-Not_AE_Candidate
Trial O
Baseline O
Creatinine O
( O
mg/dL O
) O
1.61 O
1.62 O
1.63 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
40.1 O
39.7 O
38.5 O
Week O
3 O
Change O
Creatinine O
( O
mg/dL O
) O
0.03 O
0.18 O
0.28 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-0.7 O
-4.6 O
-6.2 O
End O
of O
Treatment O
Change O
Creatinine O
( O
mg/dL O
) O
0.07 O
0.16 O
0.18 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-1.5 O
-3.6 O
-4.0 O
In O
the O
pool O
of O
four O
placebo-controlled O
trials O
where O
patients O
had O
normal O
or O
mildly O
impaired B-Not_AE_Candidate
baseline I-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
the O
proportion O
of O
patients O
who O
experienced O
at O
least O
one O
event O
of O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
, O
defined O
as O
an O
eGFR B-NonOSE_AE
below I-NonOSE_AE
8 I-NonOSE_AE
0 I-NonOSE_AE
mL I-NonOSE_AE
/ I-NonOSE_AE
min I-NonOSE_AE
/ I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
7 I-NonOSE_AE
3 I-NonOSE_AE
m I-NonOSE_AE
2 I-NonOSE_AE
and O
30 O
% O
lower O
than O
baseline O
, O
was O
2.1 O
% O
with O
placebo O
, O
2.0 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
4.1 O
% O
with O
INVOKANA O
300 O
mg O
. O
At O
the O
end O
of O
treatment O
, O
0.5 O
% O
with O
placebo O
, O
0.7 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
1.4 O
% O
with O
INVOKANA O
300 O
mg O
had O
a O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
. O

In O
a O
trial O
carried O
out O
in O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
with O
a O
baseline O
eGFR B-Not_AE_Candidate
of I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
( O
mean O
baseline O
eGFR B-Not_AE_Candidate
3 I-Not_AE_Candidate
9 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
the O
proportion O
of O
patients O
who O
experienced O
at O
least O
one O
event O
of O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
, O
defined O
as O
an O
eGFR B-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
, O
was O
6.9 O
% O
with O
placebo O
, O
18 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
22.5 O
% O
with O
INVOKANA O
300 O
mg O
. O
At O
the O
end O
of O
treatment O
, O
4.6 O
% O
with O
placebo O
, O
3.4 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
2.2 O
% O
with O
INVOKANA O
300 O
mg O
had O
a O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
. O

In O
a O
pooled O
population O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
N=1085 O
) O
with O
baseline O
eGFR B-Not_AE_Candidate
of I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 O
( O
mean O
baseline O
eGFR B-Not_AE_Candidate
4 I-Not_AE_Candidate
8 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
the O
overall O
incidence O
of O
these O
events O
was O
lower O
than O
in O
the O
dedicated O
trial O
but O
a O
dose-dependent O
increase O
in O
incident O
episodes O
of O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
compared O
to O
placebo O
was O
still O
observed O
. O

Use O
of O
INVOKANA O
has O
been O
associated O
with O
an O
increased O
incidence O
of O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
glomerular I-OSE_Labeled_AE
filtration I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
and O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
) O
, O
particularly O
in O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

In O
the O
pooled O
analysis O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
the O
incidence O
of O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
3.7 O
% O
with O
placebo O
, O
8.9 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
9.3 O
% O
with O
INVOKANA O
300 O
mg O
. O
Discontinuations O
due O
to O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurred O
in O
1.0 O
% O
with O
placebo O
, O
1.2 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
1.6 O
% O
with O
INVOKANA O
300 O
mg O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Genital O
Mycotic O
Infections O
In O
the O
pool O
of O
four O
placebo-controlled O
clinical O
trials O
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
e.g. O
, O
vulvovaginal B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
vulvovaginal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
and O
vulvovaginitis B-OSE_Labeled_AE
) O
occurred O
in O
2.8 O
% O
, O
10.6 O
% O
, O
and O
11.6 O
% O
of O
females O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Patients O
with O
a O
history O
of O
genital B-Not_AE_Candidate
mycotic I-Not_AE_Candidate
infections I-Not_AE_Candidate
were O
more O
likely O
to O
develop O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
on O
INVOKANA O
. O

Female B-NonOSE_AE
patients O
who O
developed O
genital I-NonOSE_AE
mycotic I-NonOSE_AE
infections I-NonOSE_AE
on O
INVOKANA O
were O
more O
likely O
to O
experience O
recurrence O
and O
require O
treatment O
with O
oral O
or O
topical O
antifungal O
agents O
and O
anti-microbial O
agents O
. O

In O
females B-OSE_Labeled_AE
, O
discontinuation O
due O
to O
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
in O
0 O
% O
and O
0.7 O
% O
of O
patients O
treated O
with O
placebo O
and O
INVOKANA O
, O
respectively O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

In O
the O
pool O
of O
four O
placebo-controlled O
clinical O
trials O
, O
male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
e.g. O
, O
candidal B-OSE_Labeled_AE
balanitis I-OSE_Labeled_AE
, O
balanoposthitis B-OSE_Labeled_AE
) O
occurred O
in O
0.7 O
% O
, O
4.2 O
% O
, O
and O
3.8 O
% O
of O
males O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
more O
commonly O
in O
uncircumcised O
males O
and O
in O
males O
with O
a O
prior O
history O
of O
balanitis B-Not_AE_Candidate
or O
balanoposthitis B-Not_AE_Candidate
. O

Male O
patients O
who O
developed O
genital B-NonOSE_AE
mycotic I-NonOSE_AE
infections I-NonOSE_AE
on O
INVOKANA O
were O
more O
likely O
to O
experience O
recurrent O
infections O
( O
22 O
% O
on O
INVOKANA O
versus O
none O
on O
placebo O
) O
, O
and O
require O
treatment O
with O
oral O
or O
topical O
antifungal O
agents O
and O
anti-microbial O
agents O
than O
patients O
on O
comparators O
. O

In O
males O
, O
discontinuations O
due O
to O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
in O
0 O
% O
and O
0.5 O
% O
of O
patients O
treated O
with O
placebo O
and O
INVOKANA O
, O
respectively O
. O

In O
the O
pooled O
analysis O
of O
8 O
controlled O
trials O
, O
phimosis B-OSE_Labeled_AE
was O
reported O
in O
0.3 O
% O
of O
uncircumcised O
male O
patients O
treated O
with O
INVOKANA O
and O
0.2 O
% O
required O
circumcision O
to O
treat O
the O
phimosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Hypoglycemia O
In O
all O
clinical O
trials O
, O
hypoglycemia B-NonOSE_AE
was O
defined O
as O
any O
event O
regardless O
of O
symptoms O
, O
where O
biochemical O
hypoglycemia B-NonOSE_AE
was O
documented O
( O
any O
glucose B-NonOSE_AE
value I-NonOSE_AE
below I-NonOSE_AE
or I-NonOSE_AE
equal I-NonOSE_AE
to I-NonOSE_AE
7 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
. O

Severe O
hypoglycemia B-NonOSE_AE
was O
defined O
as O
an O
event O
consistent O
with O
hypoglycemia B-NonOSE_AE
where O
the O
patient O
required O
the O
assistance O
of O
another O
person O
to O
recover O
, O
lost B-NonOSE_AE
consciousness I-NonOSE_AE
, O
or O
experienced O
a O
seizure B-NonOSE_AE
( O
regardless O
of O
whether O
biochemical O
documentation O
of O
a O
low B-NonOSE_AE
glucose I-NonOSE_AE
value I-NonOSE_AE
was O
obtained O
) O
. O

In O
individual O
clinical O
trials O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
, O
episodes O
of O
hypoglycemia B-NonOSE_AE
occurred O
at O
a O
higher O
rate O
when O
INVOKANA O
was O
co-administered O
with O
insulin O
or O
sulfonylureas O
( O
Table O
6 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

Table O
6 O
: O
Incidence O
of O
Hypoglycemia B-OSE_Labeled_AE
Number O
of O
patients O
experiencing O
at O
least O
one O
event O
of O
hypoglycemia B-OSE_Labeled_AE
based O
on O
either O
biochemically O
documented O
episodes O
or O
severe O
hypoglycemic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
intent-to-treat O
population O
in O
Controlled O
Clinical O
Studies O
Monotherapy O
( O
26 O
weeks O
) O
Placebo O
( O
N=192 O
) O
INVOKANA O
100 O
mg O
( O
N=195 O
) O
INVOKANA O
300 O
mg O
( O
N=197 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
5 O
( O
2.6 O
) O
7 O
( O
3.6 O
) O
6 O
( O
3.0 O
) O
In O
Combination O
with O
Metformin O
( O
26 O
weeks O
) O
Placebo O
+ O
Metformin O
( O
N=183 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
( O
N=368 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
( O
N=367 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
3 O
( O
1.6 O
) O
16 O
( O
4.3 O
) O
17 O
( O
4.6 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
[ O
note O
: O
Severe O
episodes O
of O
hypoglycemia B-NonOSE_AE
were O
defined O
as O
those O
where O
the O
patient O
required O
the O
assistance O
of O
another O
person O
to O
recover O
, O
lost O
consciousness O
, O
or O
experienced O
a O
seizure O
( O
regardless O
of O
whether O
biochemical O
documentation O
of O
a O
low O
glucose O
value O
was O
obtained O
) O
] O
0 O
( O
0 O
) O
1 O
( O
0.3 O
) O
1 O
( O
0.3 O
) O
In O
Combination O
with O
Metformin O
( O
52 O
weeks O
) O
Glimepiride O
+ O
Metformin O
( O
N=482 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
( O
N=483 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
( O
N=485 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
165 O
( O
34.2 O
) O
27 O
( O
5.6 O
) O
24 O
( O
4.9 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
15 O
( O
3.1 O
) O
2 O
( O
0.4 O
) O
3 O
( O
0.6 O
) O
In O
Combination O
with O
Sulfonylurea O
( O
18 O
weeks O
) O
Placebo O
+ O
Sulfonylurea O
( O
N=69 O
) O
INVOKANA O
100 O
mg O
+ O
Sulfonylurea O
( O
N=74 O
) O
INVOKANA O
300 O
mg O
+ O
Sulfonylurea O
( O
N=72 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
4 O
( O
5.8 O
) O
3 O
( O
4.1 O
) O
9 O
( O
12.5 O
) O
In O
Combination O
with O
Metformin O
+ O
Sulfonylurea O
( O
26 O
weeks O
) O
Placebo O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=156 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=157 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=156 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
24 O
( O
15.4 O
) O
43 O
( O
27.4 O
) O
47 O
( O
30.1 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
1 O
( O
0.6 O
) O
1 O
( O
0.6 O
) O
0 O
In O
Combination O
with O
Metformin O
+ O
Sulfonylurea O
( O
52 O
weeks O
) O
Sitagliptin O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=378 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=377 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
154 O
( O
40.7 O
) O
163 O
( O
43.2 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
13 O
( O
3.4 O
) O
15 O
( O
4.0 O
) O
In O
Combination O
with O
Metformin O
+ O
Pioglitazone O
( O
26 O
weeks O
) O
Placebo O
+ O
Metformin O
+ O
Pioglitazone O
( O
N=115 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
+ O
Pioglitazone O
( O
N=113 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
+ O
Pioglitazone O
( O
N=114 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
3 O
( O
2.6 O
) O
3 O
( O
2.7 O
) O
6 O
( O
5.3 O
) O
In O
Combination O
with O
Insulin O
( O
18 O
weeks O
) O
Placebo O
( O
N=565 O
) O
INVOKANA O
100 O
mg O
( O
N=566 O
) O
INVOKANA O
300 O
mg O
( O
N=587 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
208 O
( O
36.8 O
) O
279 O
( O
49.3 O
) O
285 O
( O
48.6 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
14 O
( O
2.5 O
) O
10 O
( O
1.8 O
) O
16 O
( O
2.7 O
) O
Bone O
Fracture O
The O
occurrence O
of O
bone B-NonOSE_AE
fractures I-NonOSE_AE
was O
evaluated O
in O
a O
pool O
of O
nine O
clinical O
trials O
with O
a O
mean O
duration O
of O
exposure O
to O
INVOKANA O
of O
85 O
weeks O
. O

The O
incidence O
rates O
of O
adjudicated O
bone B-OSE_Labeled_AE
fractures I-OSE_Labeled_AE
were O
1.1 O
, O
1.4 O
, O
and O
1.5 O
per O
100 O
patient-years O
of O
exposure O
in O
the O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
groups O
, O
respectively O
. O

Fractures B-OSE_Labeled_AE
were O
observed O
as O
early O
as O
12 O
weeks O
after O
treatment O
initiation O
and O
were O
more O
likely O
to O
be O
low O
trauma O
( O
e.g. O
, O
fall B-NonOSE_AE
from O
no O
more O
than O
standing O
height O
) O
, O
and O
affect O
the O
upper O
extremities O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

Laboratory O
and O
Imaging O
Tests O
Increases O
in O
Serum O
Potassium O
In O
a O
pooled O
population O
of O
patients O
( O
N=723 O
) O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
eGFR B-Not_AE_Candidate
4 I-Not_AE_Candidate
5 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
to O
greater O
than O
5.4 O
mEq/L O
and O
15 O
% O
above O
baseline O
occurred O
in O
5.3 O
% O
, O
5.0 O
% O
, O
and O
8.8 O
% O
of O
patients O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Severe O
elevations O
( O
greater O
than O
or O
equal O
to O
6.5 O
mEq/L O
) O
occurred O
in O
0.4 O
% O
of O
patients O
treated O
with O
placebo O
, O
no O
patients O
treated O
with O
INVOKANA O
100 O
mg O
, O
and O
1.3 O
% O
of O
patients O
treated O
with O
INVOKANA O
300 O
mg O
. O

In O
these O
patients O
, O
increases B-NonOSE_AE
in I-NonOSE_AE
potassium I-NonOSE_AE
were O
more O
commonly O
seen O
in O
those O
with O
elevated B-Not_AE_Candidate
potassium I-Not_AE_Candidate
at O
baseline O
. O

Among O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
approximately O
84 O
% O
were O
taking O
medications O
that O
interfere O
with O
potassium O
excretion O
, O
such O
as O
potassium-sparing O
diuretics O
, O
angiotensin-converting-enzyme O
inhibitors O
, O
and O
angiotensin-receptor O
blockers O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
and O
5.5 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

Increases O
in O
Serum O
Magnesium O
Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
magnesium I-OSE_Labeled_AE
were O
observed O
early O
after O
initiation O
of O
INVOKANA O
( O
within O
6 O
weeks O
) O
and O
remained O
elevated O
throughout O
treatment O
. O

In O
the O
pool O
of O
four O
placebo-controlled O
trials O
, O
the O
mean B-OSE_Labeled_AE
percent I-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
magnesium I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
was O
8.1 O
% O
and O
9.3 O
% O
with O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
, O
respectively O
, O
compared O
to O
-0.6 O
% O
with O
placebo O
. O

In O
a O
trial O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
serum B-OSE_Labeled_AE
magnesium I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
0.2 O
% O
, O
9.2 O
% O
, O
and O
14.8 O
% O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Increases O
in O
Serum O
Phosphate O
Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
levels O
were O
observed O
with O
INVOKANA O
. O

In O
the O
pool O
of O
four O
placebo O
controlled O
trials O
, O
the O
mean O
percent O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
were O
3.6 O
% O
and O
5.1 O
% O
with O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
, O
respectively O
, O
compared O
to O
1.5 O
% O
with O
placebo O
. O

In O
a O
trial O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
the O
mean O
serum B-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
1.2 O
% O
, O
5.0 O
% O
, O
and O
9.3 O
% O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Increases O
in O
Low-Density O
Lipoprotein O
Cholesterol O
( O
LDL-C O
) O
and O
non-High-Density O
Lipoprotein O
Cholesterol O
( O
non-HDL-C O
) O
In O
the O
pool O
of O
four O
placebo-controlled O
trials O
, O
dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
with O
INVOKANA O
were O
observed O
. O

Mean B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( I-OSE_Labeled_AE
percent I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
relative O
to O
placebo O
were O
4.4 O
mg/dL O
( O
4.5 O
% O
) O
and O
8.2 O
mg/dL O
( O
8.0 O
% O
) O
with O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

The O
mean O
baseline O
LDL-C O
levels O
were O
104 O
to O
110 O
mg/dL O
across O
treatment O
groups O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
with O
INVOKANA O
were O
observed O
. O

Mean O
changes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
percent I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
relative O
to O
placebo O
were O
2.1 O
mg/dL O
( O
1.5 O
% O
) O
and O
5.1 O
mg/dL O
( O
3.6 O
% O
) O
with O
INVOKANA O
100 O
mg O
and O
300 O
mg O
, O
respectively O
. O

The O
mean O
baseline O
non-HDL-C O
levels O
were O
140 O
to O
147 O
mg/dL O
across O
treatment O
groups O
. O

Increases O
in O
Hemoglobin O
In O
the O
pool O
of O
four O
placebo-controlled O
trials O
, O
mean O
changes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
percent I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
were O
-0.18 O
g/dL O
( O
-1.1 O
% O
) O
with O
placebo O
, O
0.47 O
g/dL O
( O
3.5 O
% O
) O
with O
INVOKANA O
100 O
mg O
, O
and O
0.51 O
g/dL O
( O
3.8 O
% O
) O
with O
INVOKANA O
300 O
mg O
. O

The O
mean O
baseline O
hemoglobin O
value O
was O
approximately O
14.1 O
g/dL O
across O
treatment O
groups O
. O

At O
the O
end O
of O
treatment O
, O
0.8 O
% O
, O
4.0 O
% O
, O
and O
2.7 O
% O
of O
patients O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
, O
had O
hemoglobin B-OSE_Labeled_AE
above I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
. O

Decreases O
in O
Bone O
Mineral O
Density O
Bone O
mineral O
density O
( O
BMD O
) O
was O
measured O
by O
dual-energy O
X-ray O
absorptiometry O
in O
a O
clinical O
trial O
of O
714 O
older O
adults O
( O
mean O
age O
64 O
years O
) O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
. O

At O
2 O
years O
, O
patients O
randomized O
to O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
had O
placebo-corrected O
declines B-OSE_Labeled_AE
in I-OSE_Labeled_AE
BMD I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the O
total O
hip O
of O
0.9 O
% O
and O
1.2 O
% O
, O
respectively O
, O
and O
at O
the O
lumbar I-OSE_Labeled_AE
spine I-OSE_Labeled_AE
of O
0.3 O
% O
and O
0.7 O
% O
, O
respectively O
. O

Additionally O
, O
placebo-adjusted O
BMD B-OSE_Labeled_AE
declines I-OSE_Labeled_AE
were O
0.1 O
% O
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
femoral O
neck O
for O
both O
INVOKANA O
doses O
and O
0.4 O
% O
at O
the O
distal I-OSE_Labeled_AE
forearm I-OSE_Labeled_AE
for O
patients O
randomized O
to O
INVOKANA O
300 O
mg O
. O

The O
placebo-adjusted O
change O
at O
the O
distal O
forearm O
for O
patients O
randomized O
to O
INVOKANA O
100 O
mg O
was O
0 O
% O
. O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
INVOKANA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Ketoacidosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Acute B-OSE_Labeled_AE
Kidney I-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Impairment B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Renal I-OSE_Labeled_AE
Function I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Anaphylaxis B-OSE_Labeled_AE
, O
Angioedema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
Urosepsis B-OSE_Labeled_AE
and O
Pyelonephritis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O

